Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

Conditions

Ischemic Stroke | Malignant Edema

What is the purpose of this trial?

This is a randomized, multi-center, prospective, double blind, two-stage, adaptive study. The primary objective is to demonstrate the efficacy of RP-1127 compared to placebo in subjects with a severe anterior circulation ischemic stroke who are likely to develop malignant edema. This objective will be addressed by comparing the proportion of RP-1127 treated patients and placebo treated patients with a Day 90 modified Rankin Scale (mRS) ≤ 4 without decompressive craniectomy (DC).


Participation Guidelines

Age:
18 - 80
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Remedy Pharmaceuticals
Dates:
05/01/2013
Last Updated:
Study HIC#:
1302011421